+

WO2000060117A3 - Prediction of risk of interstitial lung disease - Google Patents

Prediction of risk of interstitial lung disease Download PDF

Info

Publication number
WO2000060117A3
WO2000060117A3 PCT/US2000/008492 US0008492W WO0060117A3 WO 2000060117 A3 WO2000060117 A3 WO 2000060117A3 US 0008492 W US0008492 W US 0008492W WO 0060117 A3 WO0060117 A3 WO 0060117A3
Authority
WO
WIPO (PCT)
Prior art keywords
interstitial lung
prediction
risk
lung disease
ild
Prior art date
Application number
PCT/US2000/008492
Other languages
French (fr)
Other versions
WO2000060117A2 (en
Inventor
Gordon W Duff
Giovine Francesco Saverio Di
Moria Whyte
Original Assignee
Interleukin Genetics Inc
Gordon W Duff
Giovine Francesco Saverio Di
Moria Whyte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc, Gordon W Duff, Giovine Francesco Saverio Di, Moria Whyte filed Critical Interleukin Genetics Inc
Priority to JP2000609606A priority Critical patent/JP2002540801A/en
Priority to EP00921536A priority patent/EP1192275A2/en
Priority to AU41837/00A priority patent/AU779701B2/en
Priority to CA002367294A priority patent/CA2367294A1/en
Priority to IL14571400A priority patent/IL145714A0/en
Publication of WO2000060117A2 publication Critical patent/WO2000060117A2/en
Publication of WO2000060117A3 publication Critical patent/WO2000060117A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides novel methods and kits for determining whether a subject has or is likely to develop an interstitial lung disorder such as pulmonary fibrosis; as well as methods for treating an ILD and screening assays for identifying novel ILD therapeutics.
PCT/US2000/008492 1999-04-02 2000-03-31 Prediction of risk of interstitial lung disease WO2000060117A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000609606A JP2002540801A (en) 1999-04-02 2000-03-31 Predicting the risk of interstitial lung disease
EP00921536A EP1192275A2 (en) 1999-04-02 2000-03-31 Prediction of risk of interstitial lung disease
AU41837/00A AU779701B2 (en) 1999-04-02 2000-03-31 Prediction of risk of interstitial lung disease
CA002367294A CA2367294A1 (en) 1999-04-02 2000-03-31 Prediction of risk of interstitial lung disease
IL14571400A IL145714A0 (en) 1999-04-02 2000-03-31 Prediction of risk of interstitial lung disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28610899A 1999-04-02 1999-04-02
US09/286,108 1999-04-02

Publications (2)

Publication Number Publication Date
WO2000060117A2 WO2000060117A2 (en) 2000-10-12
WO2000060117A3 true WO2000060117A3 (en) 2002-02-07

Family

ID=23097113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008492 WO2000060117A2 (en) 1999-04-02 2000-03-31 Prediction of risk of interstitial lung disease

Country Status (6)

Country Link
EP (1) EP1192275A2 (en)
JP (1) JP2002540801A (en)
AU (1) AU779701B2 (en)
CA (1) CA2367294A1 (en)
IL (1) IL145714A0 (en)
WO (1) WO2000060117A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211566A1 (en) * 2000-10-10 2002-04-22 Grant W. Waterer Method for identifying increased risk of death from community acquired pneumonia
CA2470763A1 (en) * 2001-12-18 2003-06-26 Mondobiotech Laboratories Anstalt Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
US20030148288A1 (en) * 2002-02-01 2003-08-07 Yi-Wei Tang Colorimetric genetic test for clinically significant TNF polymorphism and methods of use thereof
EP1554400A1 (en) * 2002-10-15 2005-07-20 Novartis AG Methods to predict edema as a side effect of drug treatment
WO2006100446A2 (en) * 2005-03-23 2006-09-28 Astrazeneca Uk Limited Method of diagnosing interstitial lung disease (ild)
EP1888779A4 (en) * 2005-05-20 2009-06-10 Synergenz Bioscience Ltd Methods of analysis of polymorphisms and uses thereof
US8748101B2 (en) * 2008-11-10 2014-06-10 Battelle Memorial Institute Methods, compositions, and devices utilizing MicroRNA to determine physiological conditions
US20140315210A1 (en) * 2011-12-21 2014-10-23 University College Dublin, National University Of Ireland, Dublin Methods relating to idiopathic pulmonary fibrosis (ipf)
WO2014133055A1 (en) * 2013-03-01 2014-09-04 学校法人埼玉医科大学 Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting muc4 gene polymorphism

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021946A1 (en) * 1992-04-30 1993-11-11 Synergen, Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
WO1997025445A1 (en) * 1996-01-12 1997-07-17 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis by detecting an interleukin-1 receptor antagonist polymorphism
WO1998054359A1 (en) * 1997-05-29 1998-12-03 Gordon Duff Prediction of inflammatory disease associated with il-1 geneloci polymorphisms
WO1999024615A2 (en) * 1997-11-07 1999-05-20 Medical Science Systems, Inc. Diagnostics and therapeutics for chronic obstructive airway disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021946A1 (en) * 1992-04-30 1993-11-11 Synergen, Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
WO1997025445A1 (en) * 1996-01-12 1997-07-17 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis by detecting an interleukin-1 receptor antagonist polymorphism
WO1998054359A1 (en) * 1997-05-29 1998-12-03 Gordon Duff Prediction of inflammatory disease associated with il-1 geneloci polymorphisms
WO1999024615A2 (en) * 1997-11-07 1999-05-20 Medical Science Systems, Inc. Diagnostics and therapeutics for chronic obstructive airway disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRANCIS ET AL.: "Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease", CIRCULATION, vol. 99, February 1999 (1999-02-01), pages 861 - 866, XP001030756 *
HUANG SONG-LIH ET AL: "Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 156, no. 5, November 1997 (1997-11-01), pages 1436 - 1439, XP002180758, ISSN: 1073-449X *
MOFFATT MIRIAM F ET AL: "Tumour necrosis factor haplotypes and asthma.", HUMAN MOLECULAR GENETICS, vol. 6, no. 4, 1997, pages 551 - 554, XP002180759, ISSN: 0964-6906 *
WHYTE MOIRA ET AL: "Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 162, no. 2 Part 1, August 2000 (2000-08-01), pages 755 - 758, XP002180760, ISSN: 1073-449X *

Also Published As

Publication number Publication date
AU4183700A (en) 2000-10-23
AU779701B2 (en) 2005-02-10
JP2002540801A (en) 2002-12-03
WO2000060117A2 (en) 2000-10-12
EP1192275A2 (en) 2002-04-03
IL145714A0 (en) 2002-07-25
CA2367294A1 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
WO2000037679A3 (en) Method for determining the susceptibility to developing sepsis and therapeutics for the treatment of sepsis
WO1996012189A3 (en) METHODS OF SCREENING FOR ULCERATIVE COLITIS AND CROHN'S DISEASE BY DETECTING VH3-15 AUTOANTIBODY AND pANCA
AU2002257162A1 (en) Humanized antibodies
WO2001055327A8 (en) Nucleic acids, proteins, and antibodies
HK1184534A1 (en) Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 -3 -2
HK1061699A1 (en) Human anti timp-1 antibodies
WO2000060117A3 (en) Prediction of risk of interstitial lung disease
WO2000007025A3 (en) Methods for predicting drug response, in particular igf-i
WO2005118796A3 (en) Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
DK0760010T3 (en) Methods for screening for Crohn's disease using TNF microsatellite alleles
EP1130401A3 (en) Assays for measurement of type II collagen fragments in urine
WO2004020668A3 (en) Method for treating synovial sarcoma
WO2002077609A3 (en) Identification of compounds for the treatment or prevention of proliferative diseases
AU7571998A (en) Rapid evaluation of the ratio of biological molecules
WO2000043792A3 (en) Methods and kits for sequencing polypeptides
AU2003242106A1 (en) Detection kit, assay plate to be used therein, detection method, evaluation method, polyclonal antibody of frog vitellogenin and procss for producing the same
WO2003019196A3 (en) Diagnosis and treatment of atherosclerosis
WO2023245063A3 (en) Identification of tdp-43 cryptic exon-encoded neoepitopes as functional fluid biomarkers for alzheimer's disease and related dementia
DE69924617D1 (en) Immunological determination of the hydrophobic lung surfactant protein SP-C
BR9815090A (en) "nucleic acid molecules correlated with the weak rhesus d phenotype"
WO2004111272A3 (en) Polymorphism in the human nbs1 gene useful in diagnostic of inherited predisposition to cancer
WO2002067766A3 (en) Methods and material for evaluating cardiovascular conditions
EP1097944A4 (en) Antibody against protein tyrosine phosphatase intracellular domains
GB0110036D0 (en) Methods
WO1999024615A3 (en) Diagnostics and therapeutics for chronic obstructive airway disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AU BR CA CN CZ HU IL JP KR MX NO NZ PL RU SG TR US YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2367294

Country of ref document: CA

Ref country code: CA

Ref document number: 2367294

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 609606

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000921536

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AU BR CA CN CZ HU IL JP KR MX NO NZ PL RU SG TR US YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 2000921536

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载